Leqvio

Active Ingredient(s): Inclisiran
FDA Approved: * December 22, 2021
Pharm Company: * NOVARTIS PHARMS CORP
Category: Heart (Cardiac)

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Leqvio Overview

Inclisiran, sold under the brand name Leqvio, is a medication for the treatment of people with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk equivalents and heterozygous familial hypercholesterolemia (HeFH). It is a small interfering RNA that inhibits translation of the protein PCSK9.[5][6][7] Inclisiran is a small interfering RNA (siRNA) directed to PCSK9 (proprotein convertase subtilisin kexin type 9) mRNA.[2] Incl...

Read more Leqvio Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Inclisiran

Recent Leqvio Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Inclisiran
  • Injection: 284mg/1.5ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Inclisiran or a similar ingredient: (1 result)